Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 15/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 14/20 | 1.00 |
| ▸ | EGFR | P00533 | 7/20 | 1.00 |
| ▸ | FLT3 | P36888 | 4/20 | 0.78 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.78 |
| ▸ | FLT4 | P35916 | 3/20 | 0.78 |
| ▸ | AURKA | O14965 | 2/20 | 0.78 |
| ▸ | RET | P07949 | 2/20 | 0.78 |
| ▸ | FLT1 | P17948 | 2/20 | 0.78 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.78 |
| ▸ | STK3 | Q13188 | 2/20 | 0.78 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.78 |
| ▸ | GAK | O14976 | 1/20 | 0.78 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.78 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.78 |
| ▸ | LATS1 | O95835 | 1/20 | 0.78 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.78 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.78 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30676938 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4408682 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4408686 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4408521 | 0.91 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4408517 | 0.91 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4408645 | 0.90 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4408641 | 0.90 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4414238 | 0.89 | KDR (0.84) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4414235 | 0.89 | KDR (0.84) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4410831 | 0.88 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642465-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | Novocure GmbH (CH) | 2025-11-05 | — | — | EP | claimed |
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-27 | — | — | US | claimed |
| EP-4460314-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-13 | — | — | EP | claimed |
| US-20240216403-A1 | METHODS AND COMPOSITIONS FOR INHIBITING FIBROBLAST ACTIVATION | BIOPHARMA CREDIT PLC (GB) | 2024-07-04 | — | — | US | claimed |
| WO-2024141952-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | NOVOCURE GMBH (CH) | 2024-07-04 | — | — | WO | claimed |
| US-20240165199-A1 | PROX1 PREVENTS MYXOMATOUS VALVE DISEASE BY INHIBITING PDGF-B SIGNALING | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2024-05-23 | — | — | US | claimed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | claimed |
| CN-114634908-A | Direct reprogramming of human somatic cells into selected (predetermined) differentiated cells using functionalized nanoparticles | 斯特姆詹尼克斯公司 | 2022-06-17 | — | — | CN | claimed |
| US-12613236-B2 | Lung fibrosis model and methods of using the same | DUKE UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250368949-A1 | SYSTEMS AND METHODS FOR GROWING CELLS IN VITRO | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2025-12-04 | — | — | US | disclosed |
| EP-4642465-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | Novocure GmbH (CH) | 2025-11-05 | — | — | EP | disclosed |
| US-12325866-B2 | Systems and methods for growing cells in vitro | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-06-10 | — | — | US | disclosed |
| WO-2025106671-A1 | PERSONALIZED PROGENITOR CELLS | IMMORTA BIO, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4218748-A2 | BMP-MIMETICS | Christian-Albrechts-Universität zu Kiel (DE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | disclosed |
| EP-3675844-B1 | BMP-MIMETICS | UNIV KIEL CHRISTIAN ALBRECHTS (DE) | 2023-03-08 | — | — | EP | disclosed |
| US-20220341915-A1 | LUNG FIBROSIS MODEL AND METHODS OF USING THE SAME | DUKE UNIVERSITY (US) | 2022-10-27 | — | — | US | disclosed |
| EP-4034142-A1 | LUNG FIBROSIS MODEL AND METHODS OF USING THE SAME | Duke University (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | DCX, SLC10A2, CHAT | KDR 4667/4885FGFR1 2707/4885PDGFRB 1721/4885 |
| US-12613236-B2 | Lung fibrosis model and methods of using the same | FN1, ACVR1, DSP | KDR 1982/4885FGFR1 293/4885PDGFRB 493/4885 |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | KDR 4723/4885FGFR1 3680/4885PDGFRB 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.